期刊文献+

细胞色素P450 4F2基因的克隆、突变、表达和纯化 被引量:1

Clone and Expression CYP4F2 Gene and Its Variants
下载PDF
导出
摘要 目的构建人细胞色素P450 4F2基因野生型、V81G和V433M突变型表达载体,在大肠杆菌中表达并纯化出CYP4F2蛋白。方法用RT-PCR方法从人肾脏总RNA中逆转录扩增CYP4F2,将其插入克隆载体pMD18-T Simple Vector中,将测序鉴正确的CYP4F2基因N、C端改造,克隆构建重组表达载体pCWori+-CYP4F2(His)_4-WT。同时采用重叠PCR定点突变法构建pCWori +-CYP4F2 V81G(His)_4和pCWori+-CYP4F2 V433M(His)_4表达载体,分别转化至E.Coli XL-Blue中表达。结果经IPTG诱导可有效表达CYP4F2和突变体V81G与V433M,经Western blot分析可以观察到分子量为57 kD的诱导表达条带,该表达蛋白可与His-Probe多克隆抗体起特异反应。用His- bind亲和层析纯化得到了纯度较高的His融合蛋白。结论用基因工程技术在大肠杆菌中有效表达人CYP4F2基因野生型、V81G和V433M突变型蛋白、并得到了纯度较高的CYP4F2蛋白,为进一步研究其生物学功能及研制相应抗体奠定了基础。 Objective To construct the expression vectors of human cytochrome P450 (CYP) 4F2 wild type, V81G and V433M Variants and express and purify CYP4F2 protein in E. Coli XL-Blue. Methods The entire coding region of CYP4F2 gene was cloned from total RNA isolated from human kidney tissue and verified by sequencing. N and C terminal region of DNA fragments were modified and subcloned into pCWori + Vector to facility expression, pCWori +-CYP4F2 V81G(His)4 and pCWori +-CYP4F2 V433M( His)4 were constructed using overlap PCR site-directed mutagenesis method and expressed in E. Coli XL-Blue. Results After IPTG induction, CYP4F2 wild type and variants were verified by Western blot analysis. Pure recombinant CYP4F2 protein was obtained by High-affinity His-bind Purification system. Conclusion We cloned CYP4F2 to expression the wide type and variants protein in E. Coli XL-Blue in order to study the biological function and make antibody of CYP4F2.
出处 《中国分子心脏病学杂志》 CAS 2007年第5期272-276,共5页 Molecular Cardiology of China
基金 国家自然科学基金(No.30470712) 973项目(2006CB503801)资助
关键词 CYP4F2 基因克隆 突变 表达 纯化 CYP4F2 Gene clone Mutagenesis Expression Purification
  • 相关文献

参考文献15

  • 1[1]Amaral SL,Maier KG,Schippers DN,et al.CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis.Am J Physiol Heart Circ Physiol,2003,284:H1528-1535.
  • 2[2]Kaduce TL,Fang X,Harmon SD,et al.20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells.J Biol Chem,2004,279:2648-2656.
  • 3[3]Yu M,Alonso-Galicia M,Sun CW,et al.20-hydroxyeicosatetraenoic acid (20-HETE):structural determinants for renal vasoconstriction.Bioorg Med Chem,2003,11:2803-2821.
  • 4[4]Quilley J,Qiu Y,Hirt J:Inhibitors of 20-hydroxyeicosatetraenoic acid reduce renal vasoconstrictor responsiveness.J Pharmacol Exp Ther,2003,307:223-229.
  • 5[5]Randriamboavonjy V,Kiss L,Falck JR,et al.The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation.Cardiovasc Res,2005,65:487-494.
  • 6[6]Omata K,Abraham NG,Schwartzman ML:Renal cytochrome P-450-arachidonic acid metabolism:localization and hormonal regulation in SHR.Am J Physiol,1992,262:F591-599.
  • 7[7]Gainer JV,Bellamine A,Dawson EP,et al Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.Circulation,2005,111:63-69.
  • 8[8]Mayer B,Lieb W,Gotz A,et al.Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy.Hypertension,2005,46:766-771.
  • 9[9]Henry J.Barnes,Michaelp,Arlotto,et al.Expression and enzymatic activity of recombinantcytochrome P450 17 -hydroxylase in Escherichia coli.PNAS,1991,88:5597-5601.
  • 10[10]Capdevila,J,Chacos,N,Werringloer,J et al.Liver microsomal cytochrcme P-450 and the oxidative metabolism of arachidonic acid.PNAS,1981,78:5362-5366.

同被引文献25

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部